Eyebot, a startup offering a 90-second vision test kiosk that delivers doctor-verified glasses prescriptions, has secured $20 million in Series A funding.
The Boston-based startup, founded in 2021, streamlines how people access vision care by eliminating traditional obstacles such as appointment delays, limited accessibility, complex insurance requirements, and cost. Its kiosks are already found in malls, universities, retail stores, pharmacies, grocery chains, schools, and airports. Each test is free and takes only 90 seconds to complete.
According to the company, every test generates a prescription that is reviewed and approved by licensed eye doctors, ensuring the results are fast, convenient, and reliable. This new funding brings Eyebot’s total funding to more than $30 million. This comes roughly a year after the startup raised its seed round in June 2024.
Since that time, the startup has conducted more than 45,000 free vision tests and is on track to deliver over half a million tests annually.
Matthias Hofmann, co-founder and CEO of Eyebot, stated that the shift since the seed round has been dramatic. The company has moved from piloting to partnering with some of the largest companies in the U.S., launching kiosks all over the country, and delivering tens of thousands of vision tests. Revenue is scaling and the team has doubled in size. Most importantly, the model has been proven: people are using Eyebot, doctors are validating the results, and retailers are excited about the traffic it drives.
Hofmann said what sets Eyebot apart is its combination of convenience and medical assurance. Every test is reviewed by a doctor, and all prescriptions are issued under clinical supervision. If test results indicate anything unusual, patients are referred for in-person, comprehensive exams. That balance of speed plus clinical oversight earns trust.
He also noted surprising uptake at mall locations from parents with kids. They will stop between stores, try the kiosk sometimes even while holding their kids’ hands, and leave with a prescription in just a couple of minutes.
Convincing traditional eye care providers to embrace a tech-first approach was initially difficult. Early skepticism ran deep as doctors worried about accuracy and patients questioned whether a process so fast could be reliable. Hofmann says that hesitancy eased once providers learned that experienced doctors, many with more than a decade of experience, review every result.
Eyebot is in the early phases of commercialization. Its vision test is offered free to consumers. If a prescription is needed, one of the company’s doctors verifies it for a fee. Additionally, the company leases its kiosks to optical retailers, eyewear brands, and independent practices.
With the Series A funding, the company plans to scale kiosk deployment and expand its team across product, clinical operations, and commercial growth. The latest round was led by General Catalyst and included participation from returning investors AlleyCorp, Baukunst, Village Global, Humba Venture, Ravelin, and Ubiquity Ventures.